UK markets open in 6 hours 41 minutes
  • NIKKEI 225

    23,474.27
    0.00 (0.00%)
     
  • HANG SENG

    24,786.13
    +31.71 (+0.13%)
     
  • CRUDE OIL

    40.55
    -0.09 (-0.22%)
     
  • GOLD FUTURES

    1,906.10
    +1.50 (+0.08%)
     
  • DOW

    28,363.66
    +152.84 (+0.54%)
     
  • BTC-GBP

    9,870.00
    +1,415.34 (+16.74%)
     
  • CMC Crypto 200

    259.97
    +3.87 (+1.51%)
     
  • ^IXIC

    11,506.01
    +21.31 (+0.19%)
     
  • ^FTAS

    3,268.54
    +7.53 (+0.23%)
     

Hardman & Co Research: Tissue Regenix (TRX): Funded through to profitability

·2-min read

Hardman & Co Research
07-Oct-2020 / 13:50 GMT/BST

Hardman & Co Research: Funded through to profitability

TRX is focused on the development and commercialisation of two proprietary decellularisation technologies for repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of approved regenerative medicine products for the biosurgery, orthopaedics and dental markets. Over the past two years, TRX has revised its commercial strategy, restructured to service demand, and commenced a capacity expansion programme in its US facilities. As some benefits were beginning to emerge, COVID-19 caused the postponement of elective surgeries on which much of TRX's core business is derived. Despite the challenges, TRX is well positioned for growth.

Please click on the link below for the full report:

https://www.hardmanandco.com/research/corporate-research/funded-through-to-profitability/

If you are interested in meeting the company, you can register your interest by clicking on the above link

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contact:

Dr Martin Hall



+44 20 7194 7622

 

mh@hardmanandco.com

 

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contact:

Dr Martin Hall



+44 20 7194 7622

 

mh@hardmanandco.com

 

End of Announcement - EQS News Service

show this
show this